
About Dyne Therapeutics
Dyne Therapeutics is a publicly listed company based in Cambridge (United States) founded in 2017. Nucleic acid therapies for rare diseases are developed. The company has 191 employees. Its website dyne-tx.com draws about 18 thousand monthly visits. Dyne Therapeutics offers products and services including DYNE-101, DYNE-251, and DYNE-302. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Therapeutic. Its legal entity is Dyne Therapeutics, Inc. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
Dyne Therapeutics was founded in 2017 and is headquartered in Cambridge, United States. Nucleic acid therapies targeted at rare diseases, including muscle disorders such as myotonic dystrophy, are provided by the company. Proprietary technology is utilized for drug discovery and development, with focus areas encompassing linker chemistry and antibiotic engineering. Treatments for various rare genetic conditions are also advanced through these operations in the biotechnology sector.
- Headquarters Cambridge, United States
- Employees 191
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website dyne-tx.com
- Social LinkedIn X Facebook YouTube
- Legal Name Dyne Therapeutics, Inc.
- Net Profit-$446.21 M (USD)-40.58as on Dec 31, 2025
- EBITDA-$466.13 M (USD)-36.44as on Dec 31, 2025
- Latest Funding Round$115.7M (USD), Post-IPO
Aug 2020
- InvestorsCitadel
& 7 more
- Employee Count191
Products & Services of Dyne Therapeutics
Dyne Therapeutics offers a comprehensive portfolio of products and services, including DYNE-101, DYNE-251, and DYNE-302.
Targets DM1 disease to stop progression in neuromuscular patients.
Focuses on DMD disease for improved muscle function.
Addresses FSHD disease to enhance patient outcomes.
Funding Insights of Dyne Therapeutics
- Total Rounds 2
- Last Round Post-IPO — $115.7M
- First Round $50M
(Apr 2019)
- Investors Count 8
All 2 funding rounds of Dyne Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2020 | $115.7M | Post-IPO | – | – | |
| Apr 2019 | $50M | Post-IPO | – | – |
8 investors in total: 8 institutional.
Investors in Dyne Therapeutics
Dyne Therapeutics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Citadel, Atlas Venture and Vida Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biomedical innovations are transformed into therapies by Vida Ventures. | vidaventures.com | Boston, United States | ||
Private equity fund focused on the biotechnology sector | logoscapital.com | San Francisco, United States | ||
Venture capital firm focused on lifescience and healthcare sectors | forbion.com | Naarden, Netherlands | ||
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Diversified investment management services are provided to institutional clients. | wellington.com | Boston, United States | ||
Diversified investment management services are offered in India. | franklintempletonindia.com | Mumbai, India | ||
Invests in biotech firms developing life-saving drugs and technologies. | mpmcapital.com | |||
Long, short, event-driven, and multiple strategies are employed by Citadel. | 1990 | citadel.com | Chicago, United States |
Investor details for Dyne Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Dyne Therapeutics
59 people are tracked at Dyne Therapeutics (45 in leadership, 6 in board & advisors, 8 in team); the tracked headcount is 191.
| Name | Role | Group |
|---|---|---|
Robert Ciamarra | Head Of Procurement | Leadership |
Lori Ryan | Director, Clinical Quality | Leadership |
Lucia Celona | Chief Human Resources Officer | Leadership |
Oxana Beskrovnaya | Chief Innovation Officer | Leadership |
Molly White | VP, Global Head of Patient Advocacy & Engagement | Leadership |
Ashley Clark | Director, Human Resources | Leadership |
Zachary E. Hurwitz | Director, Head Of Medical Writing | Leadership |
Lisa Guarino | Director Data Management | Leadership |
Annalyn Gilchrist | Director, New Product Planning | Leadership |
Brian Newkirk | Vp, Program Team Leader And Head Of New Product Planning | Leadership |
Daniel Wilson | SVP Head Of Legal | Leadership |
Baoguang Han | Vice President, Head Of Biometrics | Leadership |
Clarence J. Wang | Vp, Head Of Data Sciences | Leadership |
Joanne Bryce | Director, Finance | Leadership |
Kate Mitchell | VP, Head of Human Resources | Leadership |
Debra Feldman | VP, Head of Regulatory | Leadership |
Cong Yao | Executive Director, Intellectual Property Senior Counsel | Leadership |
Bill Schoeninger | Director, External Reporting And Accounting | Leadership |
Ross Hanson | Senior Director, Head Of Financial Planning & Analysis | Leadership |
Iva Ivanovska Holder | Vice President, Global Head, Scientific And Medical Communications | Leadership |
39 more people are available in the full profile.
Complete people profiles for Dyne Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Dyne Therapeutics
Dyne Therapeutics is a publicly listed company on the NASDAQ with ticker symbol DYN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Sep 2020
- Listed onNASDAQ: DYN
- Listed entityDyne Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS26818M1080
- Share price$15.30 (-4.14% on the day) · 2026-10-13
- Market capitalisation$2.86B
- EPS (diluted, trailing year)$-3.33
- Volume (last session)3,341,604
Financials of Dyne Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$446.2M | -$466.1M | |
| 2024 | -$317.4M | -$341.6M | |
| 2023 | -$235.9M | -$239.7M | |
| 2022 | -$168.1M | -$167.6M | |
| 2021 | -$149.3M | -$148.9M |
Detailed financial statements for Dyne Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Dyne Therapeutics
4 dated milestones of Dyne Therapeutics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Dyne Therapeutics is founded.
- Funding First funding round of $50.0M.
- Funding Latest funding round, Post-IPO, of $115.7M.
- IPO Lists on the stock exchange (IPO).
Competitors of Dyne Therapeutics
Dyne Therapeutics has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of Dyne Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Dyne Therapeutics
The website of Dyne Therapeutics (dyne-tx.com) receives about 18K visits a month and ranks #1,573,169 among all websites worldwide, #2,100 in Biotechnology and Pharmaceuticals.
- Monthly visits18K
▲ 12% vs previous month
- Unique visitors6.9K
per month
- Global rank#1,573,169
among all websites
- Category rank#2,100
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit1.9
- Average visit1 min 26 sec
- DevicesDesktop 31% · Mobile 69%
Websites whose visitors overlap most with Dyne Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| aviditybiosciences.com | 100% | 11.7K | #1,815,056 | View details | |
| clinicaltrialsarena.com | 96% | #257,942 | View details | ||
| parentprojectmd.org | 75% | 55.1K | #526,697 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Dyne Therapeutics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Dyne Therapeutics
Complete news archive for Dyne Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dyne Therapeutics
Dyne Therapeutics was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Dyne Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Dyne Therapeutics has 191 employees.
Dyne Therapeutics was founded in 2017 and is headquartered in Cambridge, United States. Nucleic acid therapies targeted at rare diseases, including muscle disorders such as myotonic dystrophy, are provided by the company. Proprietary technology is utilized for drug discovery and development, with focus areas encompassing linker chemistry and antibiotic engineering. Treatments for various rare genetic conditions are also advanced through these operations in the biotechnology sector.
Dyne Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Alnylam.
Dyne Therapeutics offers DYNE-101, DYNE-251, and DYNE-302.
Yes, Dyne Therapeutics is publicly traded on NASDAQ under the ticker symbol DYN.
Dyne Therapeutics has 8 investors. Key investors include Citadel, Atlas Venture, Vida Ventures, Wellington, and Logos Capital.
Dyne Therapeutics operates through Dyne Therapeutics, Inc..
